

Certificate of Analysis for NR-54979

Modified path Vector Containing the Human Coronavirus, OC43 Spike Glycoprotein

Catalog No. NR-54979

This reagent is the tangible property of the U.S. Government.

Product Description:

The vector for the spike (S) glycoprotein gene from human coronavirus, OC43 (GenBank: KF572804) was designed by codon optimizing the full-length S sequence (residues 1 to 1287) for mammalian expression and subcloning into the pαH mammalian expression vector, which was modified by subcloning a T4 foldon trimerization domain, HRV3C protease cleavage site, and the octa-histidine and 2X Strep-tag® II tags downstream of the open reading frame. The recombinant protein is stabilized by AL→PP mutations (residues 1079 and 1080). NR-54979 contains the beta-lactamase gene, bla, to provide transformant selection through ampicillin resistance in Escherichia coli (E. coli). The deposited plasmid was transformed into One Shot™ TOP10 Escherichia coli (Invitrogen™ C404003), grown in Terrific broth with ampicillin (100 μg per mL) for 1 day at 37°C in an aerobic atmosphere, extracted using a Plasmid Plus Maxi Kit (QIAGEN® 12963) and vialed in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

Lot: 70043626 Manufacturing Date: 18MAY2021

TEST	SPECIFICATIONS	RESULTS
Next-Generation DNA Sequencing (pre-vial)	Report results	8,064 base pairs ¹
Genotypic Analysis Sequencing of S glycoprotein insert (~ 4,000 base pairs)	≥ 99% sequence identity to depositor's sequence C-terminal HRV3C protease cleavage site confirmed C-terminal T4 foldon trimerization domain confirmed C-terminal octa-histidine tag confirmed C-terminal 2X Strep-tag® II confirmed	100% sequence identity to depositor's sequence ² C-terminal HRV3C protease cleavage site confirmed C-terminal T4 foldon trimerization domain confirmed C-terminal octa-histidine tag confirmed C-terminal 2X Strep-tag® II confirmed
Antibiotic Resistance Ampicillin (encoded by beta-lactamase gene bla) ³	bla sequence present	bla sequence present
Agarose Gel Electrophoresis (pre-vial) Digestion with BamHI and Xhol	~ 7 kb and 300 bp	~ 7 kb and 300 bp (Figure 1)
Concentration by PicoGreen® Measurement	≥ 2 µg per mL	0.7 μg in 30 μL per vial (23 μg per mL)
Amount per Vial	Report results	0.7 μg per vial
OD ₂₆₀ /OD ₂₈₀ Ratio	1.7 to 2.1	1.9
Effective Bacterial Transformation Invitrogen™ One Shot™ TOP10 E. coli	≥ 50 colonies per ng	58 colonies per ng

¹The sequence was assembled pre-vial using the depositor's predicted sequence as the reference sequence. The complete plasmid sequence and map are provided on the BEI Resources webpage.

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org Tel: 800-359-7370

Fax: 703-365-2898


²The NR-54979 insert was codon optimized for mammalian expression but has 100% amino acid identity with human coronavirus, OC43 S glycoprotein (GenPept: AlL49484.1) other than the stabilization mutations.

³The antibiotic ampicillin degrades quickly during growth. Bacterial stationary phase should be minimized during plasmid expansion to avoid plasmid loss and increased antibiotic concentrations may be necessary.



Certificate of Analysis for NR-54979

Figure 1: Agarose Gel of Undigested and Restriction Enzyme Digested NR-54979



Lane 1: Invitrogen™ TrackIt™ 1 Kb Plus DNA Ladder

Lane 2: NR-54979 undigested Lane 3: NR-54979 digested

/Heather Couch/

Heather Couch 26 MAY 2022

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® and the contributor to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898